About YHLO
Shenzhen YHLO Biotech Co., Ltd.
YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specializing in developing, manufacturing, and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers.
In May of 2021, YHLO successfully launched IPO and was listed on Shanghai Stock Exchange (Stock code: 688575).
To be a reliable and respected IVD enterprise, YHLO has put extensive investments in R&D and is firmly associated with top-tier universities, medical schools, and research institutions worldwide on scientific studies. With over a decade's continuous development expertise in immunoassay solutions, YHLO may provide a broad range of instruments (based on Chemiluminescence, ELISA, Immunoblot, and Immunofluorescence methodologies) with patented technologies and outstanding features, as well as comprehensive total solutions with portfolios in fertility and reproductive health, diabetes, infectious diseases, autoimmune disorders, and other novel assays on rare diseases analysis.
YHLO thanks to its premium quality management has been certified by international standards, ISO 9001:2015, ISO 13485:2016, KGMP of Korea, TGA of Australia, etc. To date, YHLO has a global presence in over 110 countries around the world, our strategic alliances with multinational corporations enable us to be more competitive. Moreover, YHLO has in-depth cooperation with overseas research partners in Europe, the USA, Japan, and Australia, with the aim of developing advanced technologies and creating more medical value for the health and vitality of people all over the world.
YHLO will continue its efforts toward the mission “Focus on Healthcare, Better Life with Technology”.
YHLO Biopark
Meeting
Laboratory
+86 755 26601910
marketing@szyhlo.com
© 2020 Shenzhen YHLO Biotech Co., Ltd. All rights reserved. 粤ICP备17105123号